Michael Halstead Unloaded $459,765 Worth of Intra-Cellular Therapies, Inc. (ITCI) Stock; Pura Vida Investments Has Cut Its Nanostring Technologies (NSTG) Stake

Intra-Cellular Therapies Inc’s SVP and General Counsel Michael Halstead made a sale of 25,500 shares of the public company in a deal dated 24-01-2018. The transaction’s shares were unloaded at the avg market share price of $18.0, for a cumulative sell value of $459,765. It seems he is very active lately as in the last month, he unloaded additional 4,220 shares of the company, worth $69,179 USD. The probability of this sell staying unnoticed is quite small because it’s new, with Michael Halstead now having 191 shares – that is 0.0003% of Intra-Cellular Therapies Inc’s total market cap. as reported in a SEC Form 4 dated 24-01-2018.

Pura Vida Investments Llc decreased Nanostring Technologies Inc (NSTG) stake by 30.94% reported in 2017Q3 SEC filing. Pura Vida Investments Llc sold 123,206 shares as Nanostring Technologies Inc (NSTG)’s stock declined 7.69%. The Pura Vida Investments Llc holds 275,000 shares with $4.44B value, down from 398,206 last quarter. Nanostring Technologies Inc now has $213.72M valuation. The stock decreased 0.24% or $0.02 during the last trading session, reaching $8.42. About 173,416 shares traded. NanoString Technologies, Inc. (NASDAQ:NSTG) has risen 32.04% since January 25, 2017 and is uptrending. It has outperformed by 15.34% the S&P500.

Investors sentiment increased to 1.9 in 2017 Q3. Its up 0.23, from 1.67 in 2017Q2. It increased, as 12 investors sold NSTG shares while 17 reduced holdings. 18 funds opened positions while 37 raised stakes. 21.83 million shares or 0.18% more from 21.79 million shares in 2017Q2 were reported. Alliancebernstein Limited Partnership stated it has 15,800 shares or 0% of all its holdings. Vanguard Gp holds 841,209 shares. 28,669 were accumulated by Comml Bank Of America De. 2,226 are owned by Barclays Plc. Tiaa Cref Investment Lc holds 0% of its portfolio in NanoString Technologies, Inc. (NASDAQ:NSTG) for 83,772 shares. Weiss Multi has 0.02% invested in NanoString Technologies, Inc. (NASDAQ:NSTG) for 33,000 shares. 1.83M were accumulated by Blackrock. Aqr Management Lc holds 11,562 shares or 0% of its portfolio. Pura Vida Invs Limited Liability Com holds 275,000 shares. Moreover, Renaissance Techs Ltd has 0.01% invested in NanoString Technologies, Inc. (NASDAQ:NSTG). The New York-based Bankshares Of Mellon Corp has invested 0% in NanoString Technologies, Inc. (NASDAQ:NSTG). New York-based Levin Cap Strategies Lp has invested 0.26% in NanoString Technologies, Inc. (NASDAQ:NSTG). Mufg Americas Holdg reported 268 shares. Schwab Charles reported 0% of its portfolio in NanoString Technologies, Inc. (NASDAQ:NSTG). Citigroup holds 0% of its portfolio in NanoString Technologies, Inc. (NASDAQ:NSTG) for 859 shares.

Among 3 analysts covering NanoString Technologies (NASDAQ:NSTG), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. NanoString Technologies had 13 analyst reports since August 5, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of NSTG in report on Monday, August 14 with “Buy” rating. Cowen & Co initiated the shares of NSTG in report on Wednesday, September 30 with “Outperform” rating. Robert W. Baird maintained the stock with “Outperform” rating in Friday, November 3 report. The rating was maintained by Leerink Swann on Wednesday, August 5 with “Buy”. The company was maintained on Monday, October 23 by Robert W. Baird. The company was downgraded on Thursday, October 12 by Janney Capital. The stock of NanoString Technologies, Inc. (NASDAQ:NSTG) earned “Hold” rating by Cowen & Co on Thursday, October 12. The firm has “Hold” rating by Zacks given on Wednesday, August 12. Robert W. Baird maintained NanoString Technologies, Inc. (NASDAQ:NSTG) rating on Thursday, October 12. Robert W. Baird has “Outperform” rating and $19 target. The rating was maintained by Cowen & Co with “Hold” on Wednesday, December 20.

Pura Vida Investments Llc increased Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stake by 425,800 shares to 525,800 valued at $1.92B in 2017Q3. It also upped Penumbra Inc stake by 9,579 shares and now owns 59,579 shares. Aveo Pharmaceuticals Inc (Put) (NASDAQ:AVEO) was raised too.

Analysts await NanoString Technologies, Inc. (NASDAQ:NSTG) to report earnings on March, 7. They expect $-0.48 EPS, up 12.73% or $0.07 from last year’s $-0.55 per share. After $-0.45 actual EPS reported by NanoString Technologies, Inc. for the previous quarter, Wall Street now forecasts 6.67% negative EPS growth.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 earnings per share, up 20.31% or $0.13 from last year’s $-0.64 per share. After $-0.53 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77% EPS growth.

The stock decreased 1.42% or $0.26 during the last trading session, reaching $18.03. About 288,821 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since January 25, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Since September 29, 2017, it had 3 insider purchases, and 8 insider sales for $11.38 million activity. 4,220 shares valued at $69,179 were sold by Halstead Michael on Wednesday, January 3. Vanover Kimberly E. also sold $20,583 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, January 3. 6,604 shares were sold by Mates Sharon, worth $115,438. Davis Robert E had sold 1,115 shares worth $17,394 on Wednesday, January 3. ALAFI CAPITAL CO LLC had bought 258,065 shares worth $4.00M. Shares for $4.00 million were bought by Alafi Christopher D. ALAFI MOSHE had bought 258,065 shares worth $4.00 million on Monday, October 2.

Investors sentiment increased to 2.77 in 2017 Q3. Its up 1.91, from 0.86 in 2017Q2. It increased, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported. Barclays Public Limited Com reported 64,598 shares. Credit Suisse Ag holds 0% or 38,785 shares. Tower Research Capital Ltd Com (Trc) holds 0.01% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 4,091 shares. C Worldwide Gru A S invested in 242,156 shares. The Connecticut-based Columbus Circle has invested 0.04% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). California State Teachers Retirement Sys has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). American Century has 65,330 shares. First Mercantile stated it has 8,791 shares or 0.03% of all its holdings. Pdts Prns Limited Co has invested 0.04% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Dekabank Deutsche Girozentrale reported 0.03% stake. Moreover, Millennium Mgmt Ltd has 0.03% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 1.38M shares. Goldman Sachs Group owns 227,624 shares or 0% of their US portfolio. Financial Bank Of America De owns 805,834 shares or 0% of their US portfolio. Clough Cap Prns Ltd Partnership invested in 658,750 shares or 0.7% of the stock. Moreover, Dubuque Bank has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).